https://www.selleckchem.com/pr....oducts/nicotinamide-
There are currently three anti-interleukin-5 (IL-5) pathway-directed therapies mepolizumab, reslizumab, and benralizumab. Of these, benralizumab was most recently approved. Benralizumab is administered every 8weeks after an initial 3 doses given every 4weeks, whereas mepolizumab and reslizumab are administered every 4weeks. This convenience in benralizumab administration indicates that it is potentially beneficial for patients. Therefore, we potentially have an opportunity to change to benralizumab in patients who
Like
Comment
Share
